ruboxistaurin ruboxistaurin ruboxistaurin (proposed brand name arxxant) is an investigational drug for diabetic retinopathy being investigated by eli lilly and company. it is a member of the bisindolylmaleimide family. ruboxistaurinclinical dataatc codenonelegal statuslegal status us: not fda approved identifiers iupac name (9s)-9--6,7,10,11-tetrahydro-9h,18h-5,21:12,17-di(metheno)dibenzopyrrolooxadiazacyclohexadecine-18,20-dione cas number169939-94-0 npubchem cid153999iuphar/bps5263chemspider135727 yunii721809wqcpchemblchembl91829 ycomptox dashboard (epa)dtxsid00168775 chemical and physical dataformulac28h28n4o3molar mass468.557 g·mol−13d model (jsmol)interactive image smiles cn(c1()ccn2c=c(c(c(o)=nc3=o)=c3c(c4=cc=cc=c45)=cn5cco1)c6=cc=cc=c62)c inchi inchi=1s/c28h28n4o3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18h,11-15h2,1-2h3,(h,29,33,34)/t18-/m0/s1 ykey:zcbuqcwbwnuwsu-sfhvurjksa-n y ny (what is this?) (verify) in february 2006, lilly submitted a new drug application for ruboxistaurin, and on august 18, 2006, lilly received an approvable letter from the us fda for ruboxistaurin, with a request for an additional clinical trial, which would take 5 years to complete. lilly has not made any further request for approval and ruboxistaurin is not approved by the fda for any medical use. mechanism of action ruboxistaurin is an inhibitor of protein kinase c-beta.